Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity : Insights from the BRACE CORONA trial
Copyright © 2022 Elsevier Inc. All rights reserved..
BACKGROUND: We explored the effect of discontinuing versus continuing angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on clinical outcomes in patients with COVID-19 according to baseline disease severity.
METHODS: We randomized 659 patients with a confirmed diagnosis of COVID-19 and classified them as having mild or moderate COVID-19 disease severity at hospital presentation using blood oxygen saturation and lung imaging. The primary outcome was the mean ratio of number of days alive and out of the hospital at 30 days according to disease severity.
RESULTS: At presentation, 376 patients (57.1%) had mild and 283 (42.9%) had moderate COVID-19. In patients with mild disease, there was no significant difference in the number of days alive and out of the hospital between ACEI/ARB discontinuation (mean 23.5 [SD 6.3] days) and continuation (mean 23.8 [SD 6.5] days), with a mean ratio of 0.98 (95% CI 0.92-1.04). However, in patients with moderate disease, there were fewer days alive and out of the hospital with ACEI/ARB discontinuation (mean 19.6 [SD 9.5] days) than continuation (mean 21.6 [SD 7.6] days), with a mean ratio of 0.90 (95% CI 0.81-1.00; P-interaction = .01). The impact of discontinuing versus continuing ACEIs/ARBs on days alive and out of hospital through 30 days differed according to baseline COVID-19 disease severity.
CONCLUSIONS: Unlike patients with mild disease, patients with moderate disease who continued ACEIs/ARBs had more days alive and out of hospital through 30 days than those who discontinued ACEIs/ARBs. This suggests that ACEIs/ARBs should be continued for patients with moderate COVID-19 disease severity.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (NCT04364893).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:249 |
|---|---|
| Enthalten in: |
American heart journal - 249(2022) vom: 30. Juli, Seite 86-97 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Macedo, Ariane Vieira Scarlatelli [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiotensin Receptor Antagonists |
|---|
| Anmerkungen: |
Date Completed 30.05.2022 Date Revised 16.07.2022 published: Print-Electronic ClinicalTrials.gov: NCT04364893 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ahj.2022.04.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339347058 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339347058 | ||
| 003 | DE-627 | ||
| 005 | 20231226002709.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ahj.2022.04.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339347058 | ||
| 035 | |a (NLM)35405099 | ||
| 035 | |a (PII)S0002-8703(22)00067-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Macedo, Ariane Vieira Scarlatelli |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity |b Insights from the BRACE CORONA trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.05.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04364893 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: We explored the effect of discontinuing versus continuing angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on clinical outcomes in patients with COVID-19 according to baseline disease severity | ||
| 520 | |a METHODS: We randomized 659 patients with a confirmed diagnosis of COVID-19 and classified them as having mild or moderate COVID-19 disease severity at hospital presentation using blood oxygen saturation and lung imaging. The primary outcome was the mean ratio of number of days alive and out of the hospital at 30 days according to disease severity | ||
| 520 | |a RESULTS: At presentation, 376 patients (57.1%) had mild and 283 (42.9%) had moderate COVID-19. In patients with mild disease, there was no significant difference in the number of days alive and out of the hospital between ACEI/ARB discontinuation (mean 23.5 [SD 6.3] days) and continuation (mean 23.8 [SD 6.5] days), with a mean ratio of 0.98 (95% CI 0.92-1.04). However, in patients with moderate disease, there were fewer days alive and out of the hospital with ACEI/ARB discontinuation (mean 19.6 [SD 9.5] days) than continuation (mean 21.6 [SD 7.6] days), with a mean ratio of 0.90 (95% CI 0.81-1.00; P-interaction = .01). The impact of discontinuing versus continuing ACEIs/ARBs on days alive and out of hospital through 30 days differed according to baseline COVID-19 disease severity | ||
| 520 | |a CONCLUSIONS: Unlike patients with mild disease, patients with moderate disease who continued ACEIs/ARBs had more days alive and out of hospital through 30 days than those who discontinued ACEIs/ARBs. This suggests that ACEIs/ARBs should be continued for patients with moderate COVID-19 disease severity | ||
| 520 | |a CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (NCT04364893) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 700 | 1 | |a de Barros E Silva, Pedro Gabriel Melo |e verfasserin |4 aut | |
| 700 | 1 | |a de Paula, Thiago Ceccatto |e verfasserin |4 aut | |
| 700 | 1 | |a Moll-Bernardes, Renata Junqueira |e verfasserin |4 aut | |
| 700 | 1 | |a Mendonça Dos Santos, Tiago |e verfasserin |4 aut | |
| 700 | 1 | |a Mazza, Lilian |e verfasserin |4 aut | |
| 700 | 1 | |a Feldman, Andre |e verfasserin |4 aut | |
| 700 | 1 | |a Arruda, Guilherme D Andréa Saba |e verfasserin |4 aut | |
| 700 | 1 | |a de Albuquerque, Denílson Campos |e verfasserin |4 aut | |
| 700 | 1 | |a de Sousa, Andrea Silvestre |e verfasserin |4 aut | |
| 700 | 1 | |a de Souza, Olga Ferreira |e verfasserin |4 aut | |
| 700 | 1 | |a Gibson, C Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Granger, Christopher B |e verfasserin |4 aut | |
| 700 | 1 | |a Alexander, John H |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, Renato D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American heart journal |d 1945 |g 249(2022) vom: 30. Juli, Seite 86-97 |w (DE-627)NLM000012270 |x 1097-6744 |7 nnns |
| 773 | 1 | 8 | |g volume:249 |g year:2022 |g day:30 |g month:07 |g pages:86-97 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ahj.2022.04.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 249 |j 2022 |b 30 |c 07 |h 86-97 | ||